GBP5 and glioblastoma: Pairing GBP inhibitors with chemotherapy (e.g., paclitaxel, temozolomide) or immune checkpoint blockers (e.g., PD-L1, CTLA-4) could overcome resistance, as seen with GBP5 in breast cancer and GBP3 in glioblastoma—a strategy testable in clinical trials or preclinical models [33,53,71,73,75].